In vivo anti-tumor role of DOX-PCL₆₃-b-PNVP₉₀ micelles.

Abstract

<p>Therapy started at 96×10⁴ tumor cells (DL) were injected i.p. in to AKR mice (n = 12/group) and referred as day 0. Lymphoma bearing animals were injected with nine doses of free DOX or, DOX-PCL₆₃-b-PNVP₉₀ micelles at a dose of 3 mg kg^-1 of body weight doxorubicin as indicated by the arrows for 3 weeks (A). All together 9 doses were given in PBS; out of 9 doses, 4 doses were given every day (from day 0 to Day 4) and remaining 5 dose were given from day 10 at an interval of 48 h and continued up to day 18. The animals in study responded to the therapy with DOX-PCL₆₃-b-PNVP₉₀ (B). Kaplan-Mayer survival analysis of tumor bearing mice was performed following therapy and was analyzed for the percent survival up to day 50 post tumor transplant by log-rank test using Graph Pad PRISM software (C). Abdominal circumference (D) and body weight (E) are depicted demonstrating the effects of the treatment on the tumor growth of the animals. Representative images of spleen, liver, heart, lung, and kidney from each treatment group (F) and the corresponding weight of excised organ following drug treatment compared to untreated control are shown (G) n = 3.</p